Lutetium (177Lu) vipivotide tetraxetan (PluvictoTM) (Figure 5) is indicated for the treatment and detection of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer. Here, FOLH1 is linked to prostate carcinoma.